Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by juniper88on Jul 11, 2019 7:01pm

90 Views

Post# 29910934

RE:RE:RE:RE:RE:RE:CC

scarlet1967 wrote:
Wino115 wrote: But it's a mixture of some taking vials every 2 weeks and some on starter dose, so you can't evenly divide the 84,600 quarterly. That would up the number by some factor. They ended last quarter around 400 or so and it grew, so logically they should be higher. As they grow usage, it's getting harder to take the number and back out a patient count.

You are absolutely right they can’t have less patients than last quarter yet generate 13.6% sale growth.

Remember too that TH revenue comes from sales to the distributor, not sales directly to the patient.

Bullboard Posts

POET increases production capacity to meet AI demand